



Eli Lilly and Company Limited Lilly House Priestley Road Basingstoke Hampshire RG24 9NL

Tel: +44 (0) 1256 315000

Medical and Product Information: +44 (0) 1256 315999

2020 EFPIA Patient Organisation Methodological Note – Eli Lilly and Company – United Kingdom

Patient organisations are a key driving force in allowing the pharma industry to become more patient centric; they provide valuable insight into the development and improvement of innovative treatments and practices.

Relationships between pharma companies and patient organisations are regulated through the EFPIA Code and national industry codes to enforce public disclosure of any collaboration. It is integral to follow these guidelines to meet and maintain high standards of transparency and integrity between the pharma industry and patient organisations across Europe.

This Methodological Note is intended to serve as supporting documentation for the Lilly patient organisation report published annually. It underlines the rationale for interactions between Lilly and patient organisations and describes the methods applied to meet the reporting requirements outlined in the EFPIA Disclosure Code and local transparency guidelines where applicable.

Patient Organisations are described as a non-for-profit legal person/entity (including the umbrella organisation to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and which business address, place of incorporation or primary place of operation is in Europe.

The patient organisation report for each country will outline:

- The type of support Lilly are providing to the patient organisation i.e. financial, indirect, or significant non-financial support
- The nature of funding or project description for every transaction
- The transaction amount in local currency if there is a monetary value attached

Cross Border Transfer of Values

Lilly define cross-border ToV as a Transfer of Value to a patient organisation where the Lilly division providing the funding is based outside of the country of the benefitting patient organisation. These ToVs are disclosed in the country where the patient organisation has been registered. These cross border ToVs are included in the relevant patient organisation reports as 'International support'.

Charitable Donations

Every year Lilly employees under the guidance of the Corporate Social Responsibility team engage in a variety of fundraising activities and initiatives for charitable organisations, to which Lilly may also contribute.

COVID-19

As per EFPIA guidance, all EFPIA Member Companies must provide detailed explanations on the consequences of COVID-19 on the disclosure data in their methodological note if applicable.

The COVID-19 pandemic has led to new ways of working for pharmaceutical companies, which have replaced in-office visits and face-to face congresses with virtual engagements to maintain dialogue and scientific exchange with the medical community while protecting the health and safety of patients, healthcare professionals and their own employees. It is important to ensure that any transactions arising due to the pandemic are reflected in the patient org report if they are deemed reportable and have a monetary value or significant non-financial value associated with them. For example, there may have been an increase in virtual campaigns or collaborations with Patient organisations to facilitate partnership during travel restrictions. There were also many donations of personal protective equipment during 2020 and if donations of this type were made to patient organisations, it is important

they are reported to ensure Lilly is adhering to the ethical guidance in light of COVID-19 which has been reflected in the updated EFPIA Code of practice.

Report Regeneration

Regarding report corrections, once reports have been published, data corrections may require updates to reports that are publicly available. Once revisions have been made, the publicly available reports may need to be updated to reflect the changes.

Published Date: The publication date equals the date the report is generated via internal systems.

This data will remain published for 3 years in the public domain.